Institute of Clinical Neuroimmunology, Biomedical Center and University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.
Institute of Clinical Neuroimmunology, Biomedical Center and University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany/The Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.
Mult Scler. 2018 Jun;24(7):991-994. doi: 10.1177/1352458517731913. Epub 2017 Sep 18.
Fingolimod is an effective treatment for active relapsing-remitting multiple sclerosis (MS). Discontinuation of therapy may be followed by recurrence of disease activity. Thus, female MS patients may be at risk of relapse during pregnancy after stopping fingolimod.
To report the disease course during pregnancy of five women who interrupted therapy with fingolimod for pregnancy.
All patients experienced relapses during pregnancy and/or postpartum after stopping fingolimod.
The risk of recurrence of disease activity during pregnancy after stopping fingolimod may be substantial. This should be considered and discussed with MS patients who are planning to become pregnant.
芬戈莫德是一种治疗活跃复发缓解型多发性硬化症（MS）的有效药物。停止治疗后可能会出现疾病活动复发。因此，女性 MS 患者在停止使用芬戈莫德后怀孕时可能有复发的风险。
报告五名因怀孕而中断芬戈莫德治疗的女性患者的疾病过程。
所有患者在停止芬戈莫德治疗后怀孕期间和/或产后均经历了疾病复发。
停止芬戈莫德治疗后怀孕时疾病活动复发的风险可能相当大。这一点应该在计划怀孕的 MS 患者中进行考虑和讨论。
